Clinical Trial Update: Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients. [Phase 3]

View source ↗

Summary

A Phase 3 maintenance trial evaluated the safety and efficacy of quetiapine sustained-release for generalized anxiety disorder and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• Quetiapine SR (quetiapine)

Snippet

Sponsor: AstraZeneca | Conditions: Anxiety Disorders | Phase 3 | Status: COMPLETED